Impact on medical cost, cumulative survival, and cost-effectiveness of adding rituximab to first-line chemotherapy for follicular lymphoma in elderly patients: An observational cohort study based on SEER-medicare
Robert I. Griffiths, Michelle L. Gleeson, Joseph Mikhael, Mark D. Danese
Dive into the research topics of 'Impact on medical cost, cumulative survival, and cost-effectiveness of adding rituximab to first-line chemotherapy for follicular lymphoma in elderly patients: An observational cohort study based on SEER-medicare'. Together they form a unique fingerprint.